In a phase II study, AD patients treated with telazorlimab demonstrated suppression of Th2, Th1, and Th17/Th22 cytokines in the treatment arm with reductions in OX40+ T cells and OX40L+ dendritic cells. Here, TNFSF4 is linked to Alzheimer disease.